+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Idiopathic Pulmonary Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 510 Pages
  • August 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5654098
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Pulmonary Fibrosis - Drugs In Development, 2022, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Pulmonary Fibrosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 24, 52, 12, 134, 38 and 5 respectively. Similarly, the Universities portfolio in Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 10 and 4 molecules, respectively.

Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Report Coverage
  • Idiopathic Pulmonary Fibrosis - Overview
  • Idiopathic Pulmonary Fibrosis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Idiopathic Pulmonary Fibrosis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development
  • Idiopathic Pulmonary Fibrosis - Drug Profiles
  • Idiopathic Pulmonary Fibrosis - Dormant Projects
  • Idiopathic Pulmonary Fibrosis - Discontinued Products
  • Idiopathic Pulmonary Fibrosis - Product Development Milestones
  • Featured News & Press Releases
  • Oct 05, 2022: Vicore announces multiple scientific abstracts and presentations at upcoming conferences during the autumn
  • Sep 06, 2022: NXP002 data to be presented at the 2022 European Respiratory Society Congress
  • Aug 17, 2022: Arrowhead files for regulatory clearance to initiate phase 1/2a study of ARO-MMP7 for idiopathic pulmonary fibrosis
  • Aug 17, 2022: Vicore IPF interim data selected as an oral “late-breaker” at the ERS congress
  • Aug 15, 2022: Bridge Biotherapeutics receives FDA authorization to proceed with phase 2 study of BBT-877
  • Aug 10, 2022: Nuformix : NXP002 successful completion of tolerability studies
  • Aug 03, 2022: Algernon Pharmaceuticals invited to present phase 2 IPF and chronic cough study data at 9th American Cough Conference
  • Aug 02, 2022: Elixiron Immunotherapeutics announces orphan drug designation granted to CSF-1R inhibitor, EI-1071 for the treatment of idiopathic pulmonary fibrosis
  • Jul 28, 2022: Algernon Pharmaceuticals reports additional positive data from its phase 2 study of Ifenprodil for IPF and chronic cough
  • Jul 20, 2022: Daewoong Pharmaceutical gets first Korean US FDA fast-track for new idiopathic pulmonary fibrosis drug
  • Jul 11, 2022: Pliant reports positive data from Phase IIa idiopathic pulmonary fibrosis trial
  • Jul 04, 2022: AD-214 program modified to maximise partnering options, extends cash runway
  • Jun 30, 2022: PureTech initiates late-stage clinical study of wholly-owned candidate LYT-100 (deupirfenidone) in IPF
  • Jun 27, 2022: Nuformix : NXP002 Update
  • Jun 24, 2022: Daewoong Pharmaceutical begins multinational phase 2 clinical trial for DWN12088, a new drug for idiopathic pulmonary fibrosis
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development for Idiopathic Pulmonary Fibrosis, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Idiopathic Pulmonary Fibrosis - Dormant Projects, 2022
  • Idiopathic Pulmonary Fibrosis - Discontinued Products, 2022
List of Figures
  • Number of Products under Development for Idiopathic Pulmonary Fibrosis, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Top 10 Routes of Administration, 2022
  • Number of Products by Stage and Top 10 Routes of Administration, 2022
  • Number of Products by Top 10 Molecule Types, 2022
  • Number of Products by Stage and Top 10 Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 3+2 Pharma LLC
  • 9 Meters Biopharma Inc
  • AbbVie Inc
  • Accendatech Co Ltd
  • Accro Bioscience Suzhou Co Ltd
  • AdAlta Ltd
  • Aeon Respire Inc
  • Afimmune Biopharma Ltd
  • AgomAb Therapeutics NV
  • Akeso Inc
  • Algernon Pharmaceuticals Inc
  • Altavant Sciences Inc
  • Altay Therapeutics Inc
  • Aluda Pharmaceuticals Inc
  • Alveolus Bio Inc
  • Amgen Inc
  • AmMax Bio Inc
  • Amniotics AB
  • Amplia Therapeutics Ltd
  • AnaMar AB
  • Angion Biomedica Corp
  • Annji Pharmaceutical Co Ltd
  • Apaxen
  • APIE Therapeutics Inc
  • Aqua Therapeutics Co Ltd
  • Aqualung Therapeutics Corp
  • Aria Pharmaceuticals Inc
  • Arrowhead Pharmaceuticals Inc
  • Arroyo BioSciences LLC
  • Asahi Kasei Pharma Corp
  • AstraZeneca Plc
  • Atrapos Therapeutics LLC
  • AusBio Ltd
  • Avalyn Pharma Inc
  • BerGenBio ASA
  • Blade Therapeutics Inc
  • Boehringer Ingelheim International GmbH
  • Bonac Corp
  • BreStem Therapeutics Inc
  • Bridge Biotherapeutics Inc
  • Bristol-Myers Squibb Co
  • CellCure
  • CellionBioMed Inc
  • Celon Pharma SA
  • Centessa Pharmaceuticals Plc
  • Certa Therapeutics Pty Ltd
  • Chemomab Therapeutics Ltd
  • Chengdu Huitai Biomedicine Co Ltd
  • Chiesi Farmaceutici SpA
  • Chong Kun Dang Pharmaceutical Corporation
  • Citryll BV
  • CohBar Inc
  • Collaborations Pharmaceuticals Inc
  • CrystalGenomics Inc
  • CSL Ltd
  • Cynata Therapeutics Ltd
  • Cytonus Therapeutics Inc
  • Daewoong Pharmaceutical Co Ltd
  • DICE Therapeutics Inc
  • DisperSol Technologies LLC
  • e-Therapeutics Plc
  • EffectorBio Inc
  • Elixiron Immunotherapeutics Inc
  • EmphyCorp Inc
  • Endogena Therapeutics Inc
  • Epigen Biosciences Inc
  • Epitracker Inc
  • ethris GmbH
  • Excalibur Pharmaceuticals Inc
  • Exorphia Co Ltd
  • Eyestem Research Pvt Ltd
  • F. Hoffmann-La Roche Ltd
  • Faknostics LLC
  • FibroGen Inc
  • FibroStatin SL
  • Foresee Pharmaceuticals Co Ltd
  • Galapagos NV
  • Galecto Inc
  • Genetic Intelligence Inc
  • Genflow Biosciences Srl
  • GenKyoTex SA
  • Genome Protection Inc
  • Genosco Inc
  • Global Blood Therapeutics Inc
  • Guangdong Zhongsheng Pharmaceutical Co Ltd
  • H4Orphan Pharma
  • Halo Therapeutics Ltd
  • Hangzhou Metai Pharmaceutical Technology Co Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • HCW Biologics Inc
  • HEC Pharma Co Ltd
  • Heilongjiang ZBD Pharmaceutical Co Ltd
  • Horizon Therapeutics Plc
  • Hubei Bio-Pharmaceutical Industrial Technological Institute Inc
  • iBio Inc
  • Imago Pharmaceuticals Inc
  • Immunomet Therapeutics Inc
  • inCerebro Co Ltd
  • Innovative Precision Medicine Group
  • InSilico Medicine
  • INVENT Pharmaceuticals Inc
  • Inventiva SA
  • iOnctura SA
  • Ionis Pharmaceuticals Inc
  • Isarna Therapeutics GmbH
  • Iterion Therapeutics Inc
  • J2H Biotech
  • Jiangsu Hengrui Medicine Co Ltd
  • JW Pharmaceutical Corp
  • Kadmon Holdings Inc
  • KBP Biosciences Co Ltd
  • Kinarus AG
  • Kither Biotech Srl
  • Kyorin Pharmaceutical Co Ltd
  • Lamellar Biomedical Ltd
  • Lanier Biotherapeutics Inc
  • Lassen Therapeutics 1 Inc
  • Lignamed LLC
  • Lispiro LLC
  • LTT Bio-Pharma Co Ltd
  • Lung Therapeutics Inc
  • MannKind Corp
  • Max Biopharma Inc
  • MD Healthcare Inc
  • MDI Therapeutics Inc
  • Medibiofarma SL
  • Metagone Biotech Inc
  • Metera Pharmaceuticals Inc
  • Mission Therapeutics Ltd
  • MitoImmune Therapeutics Inc
  • Molecure SA
  • MyMD Pharmaceuticals, Inc
  • National Institutes of Pharmaceutical R&D Co Ltd
  • NB Health Laboratory Co Ltd
  • New Amsterdam Sciences Inc
  • Nexel Co Ltd
  • Nextgen Bioscience
  • Nogra Pharma Ltd
  • Novartis AG
  • Novo Nordisk AS
  • NovoMedix LLC
  • Nuformix Plc
  • Oasis Pharmaceuticals LLC
  • Ocean Biomedical Inc
  • Oleolive LLC
  • OliX Pharmaceuticals Inc
  • Omega Therapeutics Inc
  • Onegene Biotechnology Inc
  • Opsidio LLC
  • OptiKira LLC
  • OROX BioSciences Inc
  • Oxcia AB
  • Palo BioFarma SL
  • Panorama Researchama Research
  • Pharmaxis Ltd
  • Pieris Pharmaceuticals Inc
  • Pliant Therapeutics Inc
  • Prasan Pharmaceutical Consultants LLC
  • PRISM Pharma Co Ltd
  • Pulmatrix Inc
  • Pulmongene Ltd
  • PulmoSIM Therapeutics
  • Puretech Health Plc
  • RDS2 Solutions Inc
  • Redx Pharma Plc
  • Regenasome Pty Ltd
  • Rejuvenation Technologies Inc
  • Resolute Pharma Inc
  • Reviva Pharmaceuticals Inc
  • Ribomic Inc
  • Rohto Pharmaceutical Co Ltd
  • Rubedo Life Sciences Inc
  • Saje Pharma LLC
  • Saniona AB
  • Segue Therapeutics LLC
  • Senolytic Therapeutics Inc
  • Shanghai Ark Biopharmaceutical Co Ltd
  • Shanghai Fosun Pharmaceutical (Group) Co Ltd
  • Shanghai Laifu Medical Technology Co Ltd
  • Shanghai Life Science & Technology
  • Shaperon Inc
  • Shijiazhuang Sagacity New Drug Development Co Ltd
  • Shionogi & Co Ltd
  • Sichuan Haisco Pharmaceutical Co Ltd
  • SignalRx Pharmaceuticals Inc
  • Silurian Pharmaceuticals Inc
  • Sino Biopharmaceutical Ltd
  • SK Chemicals Co Ltd
  • Structure Therapeutics Inc
  • Surrozen Inc
  • Suzhou Regend Therapeutics Co Ltd
  • Suzhou Zelgen Biopharmaceutical Co Ltd
  • Syndax Pharmaceuticals Inc
  • SynDevRx Inc
  • Taiho Pharmaceutical Co Ltd
  • Taiwan Liposome Co Ltd
  • TaiwanJ Pharmaceuticals Co Ltd
  • Telomere Therapeutics
  • Tetragenetics Inc
  • Thirona Bio Inc
  • Tiziana Life Sciences Plc
  • Topadur Pharma AG
  • TRACON Pharmaceuticals Inc
  • Translate Bio Inc
  • Tvardi Therapeutics Inc
  • Ube Industries Ltd
  • United Therapeutics Corp
  • Unity Biotechnology Inc
  • Vectus Biosystems Ltd
  • Velvio GmbH
  • Verona Pharma Plc
  • Vicore Pharma AB
  • Viridian Therapeutics Inc
  • Wuhan LL Science and Technology Development Co Ltd
  • Xfibra Inc
  • Yungjin Pharm Co Ltd